An overview of the NHS bodies and organizations relevant to the approval of digital therapeutics in the UK
The United Kingdom, as one of the world’s leading economies, is an attractive market for any digital therapeutics (DTx) or digital health company.
The UK National Health Service (NHS) is considered to be one of the world’s leading health services and has a complex structure with several bodies and organizations, of which DTx companies should be aware if they wish to launch a solution and receive reimbursement.
In this paper, we provide an overview of NHS bodies and organizations, a brief description of their roles, and further information on standards relevant to DTx companies.
Request the full whitepaper, exclusive to life science companies.